Market Size & Trends
The U.S. companion animal cardiac pharmaceuticals market size was estimated at USD 776.29 million in 2024 and is projected reach USD 1.49 billion by 2033, growing at a CAGR of 7.76% from 2025 to 2033. The key factors responsible for driving the market growth include the rising incidence of heart diseases in pets, increasing pet health expenditure, and increasing research and development.
For instance, according to an article published by Small Door Inc., Congestive heart failure (CHF) is relatively prevalent in dogs, affecting around 10% of the overall canine population and as many as 75% of older dogs who suffer from some form of heart disease.
The growing incidence of heart disease among companion animals is becoming a key driver in expanding veterinary cardiology services. As pets live longer due to general veterinary care, nutrition, and lifestyle improvements, they are more likely to develop chronic age-related conditions such as cardiovascular diseases. Veterinarians are increasingly diagnosing conditions such as valvular diseases, cardiomyopathies, and arrhythmias, which require specialized knowledge and treatment.
Veterinary cardiology has witnessed significant advancements in recent years, transforming how heart conditions in animals are diagnosed and treated. Innovations in diagnostic tools, surgical techniques, and therapeutic options are enhancing the precision of care and improving the outcomes and quality of life for pets. For instance, in April 2025, Auburn University's College of Veterinary Medicine performed a groundbreaking surgery on Hashbrown, a kitten with supravalvular mitral stenosis. This hybrid balloon valvuloplasty, a first-of-its-kind procedure for such a small and young patient, involved a collaborative effort by professionals.
The rise in innovative treatments and the increasing awareness of the importance of heart health in pets is driving growth in the veterinary cardiology industry. Pet owners increasingly seek specialized care for their animals, recognizing the availability of life-extending treatments that were once only accessible to humans. As a result, the demand for advanced veterinary cardiology services is expected to grow, further solidifying its place as a crucial component of modern veterinary medicine.
For example, in June 2024, the Indian Council for Agricultural Research published a study examining the incidence of cardiac arrhythmias in 435 dogs with a history of generalized diseases over 14 months from July 2022 to September 2023. The assessment was aimed to determine the occurrence of arrhythmias and found that 114 dogs (26.21%) displayed various types, including atrial fibrillation (30.70%), ST-segment coving, sinus arrest (9.65% each), and ST-segment elevation (8.77% each).
U.S. Companion Animal Cardiac Pharmaceuticals Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the U.S. companion animal cardiac pharmaceuticals market report based on pharmaceuticals, animal type, indication, end use, and distribution channel.Pharmaceuticals Outlook (Revenue, USD Million, 2021 - 2033)
- Pimobendan
- Spironolactone and Benazepril Hydrochloride
- Others
Animal Type Outlook (Revenue, USD Million, 2021 - 2033)
- Dogs
- Cats
- Horses
- Others
Indication Outlook (Revenue, USD Million, 2021 - 2033)
- Congestive Heart Failure
- Myocardial (Heart Muscle) Disease
- Arrhythmias
- Others
End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Veterinary Hospitals & Clinics
- Others
Distribution Channel (Revenue, USD Million, 2021 - 2033)
- Hospital/ Clinic Pharmacy
- Retail
- E-Commerce
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Companion Animal Cardiac Pharmaceuticals Market Variable Trends & Scope
Chapter 4. U.S. Companion Animal Cardiac Pharmaceuticals Market: Pharmaceuticals Estimates & Trend Analysis
Chapter 5. U.S. Companion Animal Cardiac Pharmaceuticals Market: Animal Type Estimates & Trend Analysis
Chapter 6. U.S. Companion Animal Cardiac Pharmaceuticals Market: Indication Estimates & Trend Analysis
Chapter 7. U.S. Companion Animal Cardiac Pharmaceuticals Market: By End Use Estimates & Trend Analysis
Chapter 8. U.S. Companion Animal Cardiac Pharmaceuticals Market: By Distribution Channel Estimates & Trend Analysis
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Zoetis Inc.
- Boehringer Ingelheim International Gmbh
- Merck & Co., Inc.
- Elanco
- Dechra Pharmaceuticals PLC
- Ceva Santé Animale
- Phibro Animal Health Corporation
- Virbac
- Bimeda Corporate
- Biogénesis Bagó
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | June 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 776.29 Million |
| Forecasted Market Value ( USD | $ 1490 Million |
| Compound Annual Growth Rate | 7.7% |
| Regions Covered | United States |
| No. of Companies Mentioned | 10 |
